KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Receivables (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Receivables for 13 consecutive years, with $8.6 million as the latest value for Q1 2025.

  • On a quarterly basis, Receivables rose 938.3% to $8.6 million in Q1 2025 year-over-year; TTM through Mar 2025 was $8.6 million, a 938.3% increase, with the full-year FY2024 number at $2.9 million, up 236.16% from a year prior.
  • Receivables was $8.6 million for Q1 2025 at Xenon Pharmaceuticals, up from $2.9 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $8.6 million in Q1 2025 to a low of $805000.0 in Q3 2023.
  • A 5-year average of $2.5 million and a median of $2.5 million in 2022 define the central range for Receivables.
  • Peak YoY movement for Receivables: plummeted 67.57% in 2023, then soared 938.3% in 2025.
  • Xenon Pharmaceuticals' Receivables stood at $2.8 million in 2021, then crashed by 64.34% to $986000.0 in 2022, then fell by 11.36% to $874000.0 in 2023, then skyrocketed by 236.16% to $2.9 million in 2024, then surged by 194.38% to $8.6 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Receivables are $8.6 million (Q1 2025), $2.9 million (Q4 2024), and $938000.0 (Q3 2024).